| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| LOXO-BTK-20022 | 21-44 | Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
DSSG Group: Lymphoma & blood cancers
Discontinuation Study
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Discontinuation Study | 20-28 | Multiple Myeloma in sustainable |
MRD Study
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MRD Study | 21-23 | Patients with Myeloma. |
Minimal residual disease (MRD). This is a test performed on the patients DNA at diagnosis by Next Generation Sequencing (NGS), which can detect if there are trace amounts of the cancer remaining in a patient after treatment, and has been shown to be highly predictive of long-term outcomes in several studies. |
MK2140-006 or Waveline 006
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK2140-006 or Waveline 006 | 23-16 | Selected Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter’s transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. |
MK-1026-003
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-1026-003 | 21-22 | Hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM) |
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM). |
BRUIN CLL-322
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |
MajesTEC-4
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MajesTEC-4 | 23-21 | Newly diagnosed multiple myeloma |
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant. |
AFFIRM-AL
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |